



110
1.0.0

382.1019

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: IMAMURA, et al.

Serial No.: 09/121,017

Filed: July 22, 1998

For: **HEPARIN-BINDING PROTEINS MODIFIED
WITH SUGAR CHAINS, METHOD OF
PRODUCING THE SAME AND
PHARMACEUTICAL COMPOSITIONS
CONTAINING THE SAME**

Examiner: D. Saunders

Art Unit: 1644

RESPONSE TO RESTRICTION AND SEQUENCE LISTING REQUIREMENTS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is in response to the Office Action dated August 4, 1999, having a shortened statutory period of response set to expire September 4, 1999. This response is accompanied by a petition to extend the time for response from September 4, 1999 until December 4, 1999, and the fee due under 37 C.F.R. § 1.17(a)(3). Any deficiency or overpayment should be charged or credited to Deposit Account No. 50-0552.

I hereby certify that this document and any documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to: "Assistant Commissioner for Patents, Washington, D.C. 20231" on November 29, 1999.

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

RESTRICTION REQUIREMENT

The Examiner has made a Restriction Requirement in the present Office Action, and has stated that the inventions of Group I, claims 1-6 and 14, drawn to a heparin binding glycoprotein, classified in class 530, subclass 395; Group II, claims 7-10 and 13, drawn to a method of producing a glycoprotein by an engineered cell, classified in class 435, subclass 69.1; Group III, claims 11-13, drawn to a method of chemically glycosylating a protein, classified in class 530, subclass 402+, and Group IV, claim 15, drawn to a method of covalently bonding a sugar to a natural protein, classified in class 530, subclass 402+, are distinct, each from the other.

ELECTION

Applicants hereby elect Group I, claims 1-6 and 14, drawn to a heparin binding protein, without traverse, for examination.

SEQUENCE LISTING REQUIREMENTS

The Examiner stated that the application fails to comply with the requirements of 37 C.F.R. §§ 1.821 through 1.825, and that the applicant is required to supply a computer readable form of the sequence listing, and a statement that the content of the paper and computer readable form are the same and include no new matter.

In response, Applicants herewith submit a Sequence Listing in computer readable form on the enclosed 3.5 inch computer disk, and a corresponding paper copy in compliance with 37 C.F.R. §§ 1.821-1.825. Pursuant to 37 C.F.R. §1.821(f) and (g), the undersigned hereby states that the information recorded in computer readable form is identical to the paper sequence listing. The submission herein does not include new matter.

Applicants submit that the present application is now in condition for allowance. An early and favorable action on the merits is earnestly solicited.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

A handwritten signature in black ink, appearing to read "Clifford M. Davidson", is written over a horizontal line.

Clifford M. Davidson
Reg. No. 32,728

Davidson, Davidson & Kappel, LLC
1140 Avenue of the Americas, 15th Floor
New York, New York 10036
(212) 997-1028